DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LYNPARZA

« Back to Dashboard

All Clinical Trials for LYNPARZA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01116648	Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2010-03-01	This partially randomized phase I/II trial studies the side effects and the best dose of cediranib maleate and olaparib and to see how well cediranib maleate and olaparib work compared to olaparib alone in treating patients with ovarian, fallopian tube, peritoneal, or triple-negative breast cancer that has returned after a period of improvement. Cediranib maleate may help keep cancer cells from growing by affecting their blood supply. Olaparib may stop cancer cells from growing abnormally. The combination of cediranib maleate and olaparib may help to keep cancer from growing.
NCT02032823	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer	Recruiting	Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet	Phase 3	2014-04-01	Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
NCT02032823	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer	Recruiting	Breast International Group	Phase 3	2014-04-01	Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

Clinical Trial Conditions for LYNPARZA

Condition Name

Condition Name for LYNPARZA
Intervention	Trials
Recurrent Primary Peritoneal Carcinoma	8
Recurrent Fallopian Tube Carcinoma	8
Recurrent Ovarian Carcinoma	6

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for LYNPARZA
Intervention	Trials
Adenocarcinoma	18
Carcinoma	18
Ovarian Neoplasms	16

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for LYNPARZA

Trials by Country

Trials by Country for LYNPARZA
Location	Trials
United States	274
Canada	26
Spain	9
United Kingdom	8
Italy	7

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for LYNPARZA
Location	Trials
Texas	15
Massachusetts	12
Pennsylvania	10
Illinois	10
California	10

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for LYNPARZA

Clinical Trial Phase

Clinical Trial Phase for LYNPARZA
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	7
Phase 2/Phase 3	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for LYNPARZA
Clinical Trial Phase	Trials
Not yet recruiting	43
Recruiting	32
Active, not recruiting	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for LYNPARZA

Sponsor Name

Sponsor Name for LYNPARZA
Sponsor	Trials
AstraZeneca	38
National Cancer Institute (NCI)	30
M.D. Anderson Cancer Center	8

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for LYNPARZA
Sponsor	Trials
Other	66
Industry	65
NIH	30

Export unavailable in trial.
Subscribe for complete access.